
April 25 (Reuters) - Tonix Pharmaceuticals Holding Corp TNXP.O:
TONIX PHARMACEUTICALS HOLDING CORP - DISCONTINUED ENROLLMENT AND TERMINATED PHASE 2 CATALYST STUDY - SEC FILING
TONIX PHARMACEUTICALS - EVALUATING NEW STUDY DESIGNS AND NEW ENDPOINTS FOR FURTHER DEVELOPMENT OF TNX-1300
Source text: [ID:n0001999371-25-004807]